KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: Observational analysis of 175 cases

Pathology

Volumn 47, Issue 6, 2015, Pages 551-556

  Barresi, Valeria ^a   Bonetti, Luca Reggiani ^b   Bettelli, Stefania ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

BRAF; colorectal cancer; KRAS; NRAS; poorly differentiated clusters

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

AGED; CANCER GRADING; CELL DIFFERENTIATION; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NEOPLASM GRADING; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84938644063     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000300     Document Type: Article

References (38)

1. Brenner H, Bouvier AM, Foschi R, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer 2012; 131: 1649-58.
2. Ueno H, Kajiwara Y, Shimazaki H, et al. New criteria for histologic grading of colorectal cancer. Am J Surg Pathol 2012; 36: 193-201.
3. Barresi V, Reggiani Bonetti L, Branca G, et al. Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. Virchows Arch 2012; 461: 621-8.
4. Barresi V, Bonetti LR, Ieni A, et al. Histologic grading based on counting poorly differentiated clusters in preoperative biopsy predicts nodal involvement and pTNM stage in colorectal cancer patients. Hum Pathol 2014; 45: 268-75.
5. Barresi V, Branca G, Ieni A. Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. Virchows Arch 2014; 464: 655-62.
6. Ueno H, Hase K, Hashiguchi Y, et al. Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters. Am J Surg Pathol 2014; 38: 197-204.
7. Ueno H, Hase K, Hashiguchi Y, et al. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. J Gastroenterol 2014; 49: 1314-23.
8. Barresi V, Branca G, Vitarelli E, et al. Micropapillary pattern and poorly differentiated clusters represent the same biological phenomenon in colorectal cancer: a proposal for a change in terminology. Am J Clin Pathol 2014; 142: 375-83.
9. Cancer Genome Atlas NetworkComprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
10. Imamura Y, Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wildtype colorectal cancers. Clin Cancer Res 2012; 18: 4753-63.
11. Imamura Y, Lochhead P, Yamauchi M, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014; 13: 135.
12. Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005; 54: 1283-6.
13. Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 2010; 59: 838-58.
14. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
15. Shen Y, Wang J, Han X, et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoSOne 2013; 8: e81628.
16. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 2012; 18: 890-900.
17. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18: 6531-41.
18. Hamilton SR, Bosman FT, Boffetta P, et al. Carcinoma of the colon and rectum. In: Bosman T, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press, 2010;138-9.
19. Hamilton SR, Volgelstein B, Kudo S, et al. Carcinoma of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000;110-1.
20. Ueno H, Mochizuki H, Hashiguchi Y, et al. Preoperative parameters expanding the indication of sphincter preserving surgery in patients with advanced low rectal cancer. Ann Surg 2004; 239: 34-42.
21. Ueno H, Konishi T, Ishikawa Y, et al. Prognostic value of poorly differentiated clusters in the primary tumor in patients undergoing hepatectomy for colorectal liver metastasis. Surgery 2015; 157: 899-908.
22. Barresi V, Bonetti LR. Correlation between microsatellite instability status and grading assessed by the counting of poorly differentiated clusters in colorectal cancer. Hum Pathol 2015; 46: 1063.
23. Rosty C, Williamson EJ, Clendenning M, et al. Should the grading of colorectal adenocarcinoma include microsatellite instability status? Hum Pathol 2014; 45: 2077-84.
24. Steinestel K, Lennerz JK, Eder S, et al. Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. Virchows Arch 2014; 465: 155-63.
25. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013; 26: 825-34.
26. Asaka S, Arai Y, Nishimura Y, et al. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Carcinogenesis 2009; 30: 494-9.
27. Makrodouli E, Oikonomou E, Koc M, et al. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer 2011; 10: 118.
28. Netzel BC, Grebe SK. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. Clin Chim Acta 2013; 21: 1-2.
29. Zlobec I, Bihl MP, Schwarb H, et al. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 15: 367-80.
30. Benedix F, Meyer F, Kube R, et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract 2012; 15: 592-7.
31. Lin CC, Lin JK, Lin TC, et al. The prognostic role of microsatellite instability, codon-specific KRAS,and BRAF mutations in colon cancer. J Surg Oncol 2014; 110: 451-7.
32. Verdú M, Román R, Calvo M, et al. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma. Mod Pathol 2011; 24: 729-38.
33. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600-8.
34. Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014; 3: 171-84.
35. Rachagani S, Senapati S, Chakraborty S, et al. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 2011; 15: 1038-48.
36. Satow R, Hirano T, Batori R, et al. Phospholipase Cδ1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells. Proc Natl Acad Sci USA 2014; 111: 13505-10.
37. Prall F, Ostwald C. High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. Hum Pathol 2007; 38: 1696-702.
38. Andreyev HJN, Norman AR, Cuningham D, et al. Ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer 2001; 85: 692-6.